Table 1.
Comparison of baseline characteristics of patients with and without CMV viremia.
| Variables | CMV viremia (n = 29) | No CMV viremia (n = 26) | P-value |
|---|---|---|---|
| Pretransplant data | |||
| Recipient age, years [mean (SD)] | 47.31 (10.6) | 45.7 (9.87) | 0.478 |
| Male sex, no (%) | 18 (62.1%) | 14 (53.8%) | 0.537 |
| Cause of ESRD, no (%) | |||
| Glomerular disease | 9 (31%) | 9 (34.6%) | 0.778 |
| ADPKD | 1 (3.4%) | 2 (7.7%) | 0.486 |
| Tubulointerstitial disease | 1 (3.4%) | 0 | 0.347 |
| Unknown | 17 (58.6%) | 15 (57.7%) | 0.946 |
| Comorbidities, no (%) | |||
| Hypertension | 15 (51.7%) | 11 (42.3%) | 0.485 |
| Diabetes mellitus | 5 (17.2%) | 2 (7.7%) | 0.426 |
| Dyslipidemia | 6 (20.7%) | 2 (7.7%) | 0.257 |
| Chronic liver disease | 3 (10.3%) | 2 (7.7%) | 1.000 |
| Autoimmune disease | 0 | 1 (3.8%) | 0.473 |
| Transplant data | |||
| Retransplantation | 0 | 2 (7.7%) | 0.131 |
| Donor type, deceased donor | 25 (86.2%) | 13 (50%) | 0.004 |
| Donor CMV seropositivity (D+) | 26 (89.7%) | 26 (100%) | 0.238 |
| Donor age, years [mean (SD)] | 43.4 (15.1) | 34.1 (9.1) | 0.017 |
| Induction therapy with basiliximab | 28 (96.6%) | 26 (100%) | 0.347 |
| Pretransplant leukocyte count, cells/mcl [mean (SD)] | 5,892 (1,595) | 6.503 (1,707) | 0.176 |
| Pretransplant lymphocyte count, cells/mcl [mean (SD)] | 1,245 (486) | 1,232 (453) | 0.922 |
| Cold ischemic time, hours [mean (SD)] | 17 (4) | 17 (3) | 0.870 |
| Delayed graft function, no (%) | 11 (39.3%) | 9 (33.3%) | 0.646 |
| Graft rejection | 4 (13.8%) | 0 | 0.113 |
| Prednisolone dose at 1 month, mg [mean (SD)] | 23.3 (2.9) | 17.5 (10.6) | 0.767 |
| Mycophenolate dose at 1 month, mg [mean (SD)) | 960 (208) | 405 (445) | 0.823 |
| Tacrolimus trough level at 1 month, ng/ml [mean (SD)] | 7.3 (1.3) | 8 (3) | 0.045 |
| QuantiFERON-CMV [median (range)] | 1.52 (-0.11-10) | 1.84 (-2.43-10) | 0.785 |
CMV, cytomegalovirus; SD, standard deviation; ESRD, end stage renal disease; ADPKD, adult polycystic kidney disease.